Biocon Limited (NSE: BIOCON, BSE: 532523) is a Bengaluru, Karnataka-based company in the Biological Products industry. With a market capitalisation of ₹52,675 Cr, it ranks #188 by market cap among the 6,189 Indian listed companies on FinBizNet, and #1 of 5 in Biological Products. At ₹323.50 (as of 26 Oct 2026), the share price is 27.7% below its 52-week high of ₹447.15 and 1.6% above its 52-week low of ₹318.40. The share price is down 9.7% over one year and down 25.4% over three months.
| Current Price | ₹323.50 |
|---|---|
| Market Cap | ₹52,675 Cr |
| NSE Symbol | BIOCON |
| BSE Code | 532523 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | 114.7 |
| Return on Equity | 1.15% |
| Return on Assets | 1.73% |
| 52-Week Range | ₹318.40 – ₹447.15 |
| 1-Year Price Change | -9.7% |
| 3-Month Price Change | -25.4% |
| Beta (1Y) | 0.07 |
| Dividend Yield | 0.15% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.biocon.com |
| Revenue | ₹4,336 Cr |
|---|---|
| Net Profit | ₹137 Cr |
| Net Margin | 3.2% |
| EPS (Basic) | ₹0.87 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals
1. Generics-This segment develops a portfolio of small molecule generics. 2. Biosimilars-This segment focuses on developing various biosimilars. 3. Research Services-This segment provides integrated drug discovery and development services in chemistry, biology, in vivo and in vitro pharmacology, toxicology, custom synthesis, process research and development, cGMP manufacturing, formulation, analytical development, and clinical development. 4. Inter-Segment Revenue-0
1. Biosimilars-61.6% 2. Generics-18.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Biocon Limited | ₹52,675 Cr | 114.7 | 1.15% | ₹4,336 Cr | -9.7% |
| Hester Biosciences Ltd | ₹1,744 Cr | 31.4 | 16.55% | ₹77 Cr | +19.5% |
| Zenotech Laboratories Ltd | ₹246 Cr | -223.9 | -1.12% | — | -20.3% |
| Transgene Biotek Ltd. | ₹19 Cr | -11.7 | -17.96% | ₹0 Cr | -39.2% |
| Hindustan Bio Sciences Ltd | ₹7 Cr | -86.3 | -9.12% | — | -18.7% |
Listed by market capitalisation. Ratios are shown for context only.
Biocon Limited is trading at ₹323.50, with a market capitalisation of ₹52,675 Cr.
Biocon Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Biocon Limited has a P/E of 114.7 and a return on equity of 1.15%.
Biocon Limited is listed on the NSE under the symbol BIOCON and on the BSE under the scrip code 532523.
Biocon Limited's share price is down 9.7% over one year and down 25.4% over three months. Its 52-week range is ₹318.40 to ₹447.15.
In Q1 FY27, Biocon Limited reported revenue of ₹4,336 Cr and net profit of ₹137 Cr, with basic EPS of ₹0.87 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.